ADHD and Hormones in Women: The Cycle, Perimenopause and MCAS

By Reine DuBois, Integrative Naturopath and Clinical Director – The Health Lodge

ADHD and Hormones in Women: Why Your Focus and Mood Shift Across the Month and Into Perimenopause

If you live with ADHD and you are a woman, you may have noticed something that rarely gets explained. Some weeks your focus is sharp and your medication works beautifully. Other weeks the same dose feels like it has stopped working, your emotions run closer to the surface and the simplest plan slips through your fingers. That pattern is not a failure of willpower and it is not in your head. For many women it tracks with hormones, and there is often a third and less familiar player quietly amplifying the picture: Mast Cell Activation Syndrome, or MCAS, an immune condition in which mast cells release inflammatory chemicals like histamine far too readily.

When ADHD, hormonal fluctuation and mast cell activity overlap in the same person, no single appointment with no single practitioner tends to capture the whole story. The neurologist or GP sees the ADHD. The gynaecologist or the menopause specialist sees the hormones. The allergist or immunologist sees the histamine. The psychologist sees the emotional fallout. Each is right, and each is looking at one corner of a connected system. This article explains how those three threads weave together, and why a coordinated integrative team is often what finally moves the needle.

Estrogen and dopamine: a quiet partnership in the ADHD brain

ADHD is strongly linked to the way the brain manages dopamine, the chemical messenger behind focus, motivation and executive function. Estrogen, and specifically estradiol, behaves almost like an ally to dopamine. Research describes estrogen increasing dopamine synthesis while reducing its breakdown and reuptake, which means more dopamine is available at the synapse when estrogen is high (Monash Lens, 2023; Osianlis et al., 2025).

This matters because estrogen rises and falls in a predictable rhythm across the menstrual cycle. In the follicular phase, in the lead up to ovulation, estrogen climbs. Many women report that this is when focus is clearest and when ADHD medication seems to do its best work. The reverse is also true, and that is where the trouble usually starts.

The luteal drop: why the week before your period feels harder

After ovulation, in the late luteal phase, estrogen falls away rapidly. For women who are sensitive to that shift, this is often when ADHD symptoms quietly worsen. Inattention deepens, emotional regulation becomes harder and the executive function that holds a busy life together starts to fray. Some women also feel that their usual stimulant medication is simply less effective in this window, which fits the underlying biology, because lower estrogen means less dopamine support in the brain (Monash Lens, 2023; Wynchank et al., 2025).

At the more severe end of this spectrum sits premenstrual dysphoric disorder, a debilitating form of premenstrual distress that is markedly more common in women with ADHD than in the general population. The takeaway for everyday life is encouraging rather than discouraging. These fluctuations are patterned, which means they can be anticipated, tracked and planned for rather than endured as a monthly surprise.

Perimenopause: when ADHD can flare for the first time

If the luteal drop is a monthly dip, perimenopause is the long, uneven decline. Estrogen does not glide gently downward. It swings, spikes and falls unpredictably for years before settling, and this is a period of real hormonal vulnerability for the ADHD brain.

For some women this is the moment ADHD becomes obvious for the very first time. The hormonal turbulence acts as a catalyst, and symptoms that were managed for decades, sometimes without a formal diagnosis, suddenly surface as brain fog, disorganisation and difficulty making decisions. The scale of this experience is striking. In large community surveys of women with ADHD, the majority report that the condition had its greatest life impact during their forties and fifties, and many describe the cognitive and memory changes of this decade as life altering (ADDitude survey data, 2023 to 2024).

It is worth being honest about the state of the science here, because that honesty is part of good care. A 2025 Australian systematic review led by researchers at Monash University found no empirical studies that directly investigated ADHD during menopause, even though clinical experience and preliminary reports strongly suggest a worsening of symptoms during this transition (Osianlis et al., 2025). Newer work is starting to fill the gap. A 2025 study found that ADHD-like symptoms increased as women moved from the premenopausal into the perimenopausal stage, with only partial recovery afterwards, and notably that recovery was more likely when menopause occurred naturally rather than surgically (Chapman et al., 2025). A broad 2025 review in womens health similarly maps how lower estrogen phases interact with dopamine pathways and executive function across the whole reproductive lifespan (Frontiers in Global Womens Health, 2025).

There is also a measurable emotional cost. Earlier research found that during every episode of significant hormonal change across a womans life, women with ADHD experienced a two to threefold increase in the frequency and severity of mood changes compared with what would otherwise be expected (Dorani et al., 2021). That is not a small effect, and it helps explain why hormonal transitions can feel so destabilising.

Where MCAS fits into the picture

Here is the part that most discussions of ADHD and hormones leave out. Mast cells are part of your immune systems first line of defence. They sit in your skin, gut, lungs and blood vessels, and they release histamine and other inflammatory chemicals to protect you. In MCAS these cells become overactive and release those chemicals too often, flooding the body with inflammatory signals even when there is no genuine threat (Edge Foundation, 2025).

Crucially, mast cells are not only found in the body. They also live in the brain, clustered around blood vessels and nerves. When they activate there, they can disturb neurotransmitter balance, influence dopamine pathways and drive low grade neuroinflammation, which may worsen the very symptoms that define ADHD, including distractibility, emotional reactivity and brain fog (Song et al., 2020; Edge Foundation, 2025). Emerging research has reported elevated rates of ADHD among people with mast cell activation, and has raised the possibility that calming mast cell activity may ease some neuropsychiatric symptoms (Brain, Behavior, and Immunity Health, 2025). MCAS also tends to travel in company, overlapping with conditions such as Ehlers Danlos syndrome, POTS and other inflammatory and gastrointestinal problems (The EDS Clinic).

Now layer hormones back on top. Mast cell activity is already implicated in inflammatory hormonal conditions such as endometriosis and PCOS, and the hormonal swings of the menstrual cycle and perimenopause can themselves trigger mast cells to release their contents. Timing is everything here. Histamine is cleared by an enzyme called diamine oxidase, or DAO, and one study of healthy women found that DAO levels are highest in the luteal phase, the window after ovulation when progesterone peaks (Clinical Biochemistry, 2012). That mid luteal progesterone peak appears to steady mast cells and support histamine clearance. The catch comes in the days just before your period, when progesterone falls away sharply. As that natural brake is released, mast cells become more reactive and the histamine load can spike, which is why so many women notice their worst symptoms premenstrually rather than at peak progesterone. The result can be a self reinforcing loop, where falling hormones provoke mast cell activation, mast cell activation fuels neuroinflammation and neuroinflammation deepens ADHD symptoms. This triad of ADHD, hormones and MCAS is exactly the combination that a single specialist, looking through a single lens, is most likely to miss.

Managing the whole system, not just one piece

Because three systems are interacting, sensible management works on all three at once and under appropriate clinical supervision. The strategies below are educational. None of them replaces individual advice from your own practitioners.

Track the pattern

The single most empowering first step costs nothing. Keeping a simple symptom and cycle calendar, noting focus, mood, sleep and any histamine type symptoms alongside where you are in your cycle, turns an invisible pattern into visible data. That record becomes the shared map your whole care team can work from.

Medical review of medication and hormones

For women whose ADHD clearly flares in low estrogen phases, a prescribing doctor may consider how and when ADHD medication is used across the cycle. Some case reports describe individualised, doctor supervised adjustments to stimulant dosing in the luteal phase to offset the premenstrual dip in mood and focus (Wynchank et al., 2025). In perimenopause, a doctor may also discuss whether hormone replacement therapy has a role alongside ADHD treatment to help restore cognitive balance. These are prescribing decisions that belong with a medical practitioner who knows your full history, and they are mentioned here only so you know the conversation is worth having.

It is also worth noting that common ADHD stimulants interact with the bodys histamine handling in indirect ways. While they do not appear to directly block diamine oxidase, the enzyme that clears histamine, their side effects on sleep and appetite can influence histamine levels, which is one more reason coordinated care matters when MCAS is in the mix (Tobajas et al., 2023).

Stabilising mast cells

Where MCAS is part of the picture, a doctor may oversee strategies to stabilise mast cells and reduce the histamine load. This commonly includes combining an H1 antihistamine such as cetirizine with an H2 antihistamine such as famotidine, an approach drawn from established mast cell management protocols (Edge Foundation; Song et al., 2020). Again this sits firmly within medical care, because dosing, timing and suitability are individual.

Naturopathic and nutritional support

This is where integrative naturopathic care complements the medical and psychological work rather than competing with it. Nutritional and lifestyle strategies can be tailored to reduce histamine burden, support the bodys natural histamine clearance and steady the nervous system through hormonal transitions. One nutrient of particular interest in ADHD is magnesium. A small open label pilot study of a magnesium L threonate supplement, taken in a sustained release form, reported clinical response in close to half of the adults studied, along with improvements in executive function flexibility (Surman et al., 2021). The evidence base is early and the study was small, so this is best understood as a promising avenue to explore with a practitioner rather than a guaranteed solution, and any supplement should be chosen with your full clinical picture in mind.

Psychological support

The third pillar is the mind. A psychologist helps with the executive function strategies, emotional regulation skills and self understanding that medication and supplements cannot provide on their own. This support is especially valuable during the luteal phase and perimenopause, when emotional dysregulation peaks, and it is essential for women navigating premenstrual dysphoric disorder, where the distress is real and deserves skilled care.

Clinical hypnosis deserves a special mention here as an evidence based and non hormonal option. The Menopause Society now recommends clinical hypnosis for hot flushes and night sweats based on high quality evidence, and a randomized controlled trial found that women receiving clinical hypnosis reported around a 74 percent reduction in hot flush frequency compared with about 17 percent for the control group (Elkins et al., 2013; Menopause Society position statement). For women whose perimenopause brings broken sleep and a heavier symptom load on top of ADHD, this is a genuinely useful addition to the psychological toolkit, even though the strongest evidence is for vasomotor symptoms rather than for ADHD itself.

Why an integrative team is the difference

Read back over those four areas. Medication and hormone decisions sit with a doctor. Mast cell stabilisation sits with a doctor. Nutritional and naturopathic support sits with a naturopath. Emotional and executive function work sits with a psychologist. The cycle and symptom tracking belongs to you, and it only becomes powerful when every member of the team is reading from the same map.

This is the heart of the matter. ADHD, hormones and MCAS form a connected, whole body system, and fragmented care that treats one thread at a time will keep missing the way they pull on each other. A truly integrative model, where a naturopath, a doctor and a psychologist communicate and build a shared plan around the unique biochemistry of the individual woman in front of them, is not a luxury. For this particular triad it is the approach most likely to work.

Where to start

At The Health Lodge, care of this kind begins with an initial consultation with Reine DuBois, integrative naturopath and clinical director, who listens to the whole picture and helps coordinate the right combination of medical, naturopathic and psychological support around you. If the pattern described in this article feels familiar, that conversation is a good place to begin.

This article is for general education and does not replace individual medical advice. ADHD medication, hormone replacement therapy and mast cell treatments are prescribing decisions that must be made with a qualified medical practitioner who knows your history. Please speak with your own practitioners before changing any treatment.

References

1. Edge Foundation. ADHD and Mast Cell Activation Syndrome: When the Bodys Defense System Goes into Overdrive.
2. Song Y, et al. (2020). Mast cell mediated neuroinflammation may have a role in attention deficit hyperactivity disorder (Review). Experimental and Therapeutic Medicine.
3. Brain, Behavior, and Immunity Health (2025). Prevalence and treatment response of neuropsychiatric disorders in mast cell activation syndrome.
4. The EDS Clinic. Mast Cell Activation is linked to a wide range of other conditions.
5. Tobajas Y, et al. (2023). Interaction of Diamine Oxidase with Psychostimulant Drugs for ADHD Management. Journal of Clinical Medicine.
6. Surman C, et al. (2021). L Threonic Acid Magnesium Salt Supplementation in ADHD: An Open Label Pilot Study. Journal of Dietary Supplements.
7. Wynchank D, et al. (2025). Practical tools for female specific ADHD: the impact of hormonal fluctuations in clinical practice and from the literature. European Psychiatry.
8. Monash Lens (2023). How hormones and the menstrual cycle can affect women with ADHD.
9. Osianlis E, Thomas EHX, Jenkins LM, Gurvich C (2025). ADHD and Sex Hormones in Females: A Systematic Review. Journal of Attention Disorders.
10. Chapman L, Gupta K, Hunter MS, Dommett EJ (2025). Examining the Link Between ADHD Symptoms and Menopausal Experiences. Journal of Attention Disorders.
11. Research advances and future directions in female ADHD: the lifelong interplay of hormonal fluctuations with mood, cognition and disease (2025). Frontiers in Global Womens Health.
12. Perimenopausal symptoms in women with and without ADHD: a population based cohort study (2025).
13. Dorani F, et al. (2021). Hormonal sensitivity of mood symptoms in women with ADHD across the lifespan.
14. Elkins GR, Fisher WI, Johnson AK, et al. (2013). Clinical Hypnosis in the Treatment of Postmenopausal Hot Flashes: A Randomized Controlled Trial. Menopause.
15. The Menopause Society. Position statement recommending clinical hypnosis for vasomotor symptoms (level 1 evidence).
16. Effect of the menstrual cycle on serum diamine oxidase levels in healthy women (2012). Clinical Biochemistry.